These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 14506831

  • 1. A novel type hypertriglyceridemia observed in FLS mice.
    Takahashi M, Saibara T, Nemoto Y, Ono M, Akisawa N, Iwasaki S, Toda K, Ogawa Y, Wakatsuki A, Inagaki S, Onishi S.
    Lipids; 2003 Jul; 38(7):687-92. PubMed ID: 14506831
    [Abstract] [Full Text] [Related]

  • 2. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J, Escolà-Gil JC, Rotllan N, Fiévet C, Vallez E, de la Torre C, Ribas V, Sloan JH, Blanco-Vaca F.
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [Abstract] [Full Text] [Related]

  • 3. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
    Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G.
    J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
    [Abstract] [Full Text] [Related]

  • 4. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.
    Berbée JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC.
    J Lipid Res; 2005 Feb; 46(2):297-306. PubMed ID: 15576844
    [Abstract] [Full Text] [Related]

  • 5. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
    Wang CS, McConathy WJ, Kloer HU, Alaupovic P.
    J Clin Invest; 1985 Feb; 75(2):384-90. PubMed ID: 3973011
    [Abstract] [Full Text] [Related]

  • 6. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
    Wolska A, Lo L, Sviridov DO, Pourmousa M, Pryor M, Ghosh SS, Kakkar R, Davidson M, Wilson S, Pastor RW, Goldberg IJ, Basu D, Drake SK, Cougnoux A, Wu MJ, Neher SB, Freeman LA, Tang J, Amar M, Devalaraja M, Remaley AT.
    Sci Transl Med; 2020 Jan 29; 12(528):. PubMed ID: 31996466
    [Abstract] [Full Text] [Related]

  • 7. The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type IV subjects.
    Catapano AL.
    Atherosclerosis; 1980 Apr 29; 35(4):419-24. PubMed ID: 7378122
    [Abstract] [Full Text] [Related]

  • 8. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice.
    Allan CM, Taylor JM.
    J Lipid Res; 1996 Jul 29; 37(7):1510-8. PubMed ID: 8827523
    [Abstract] [Full Text] [Related]

  • 9. A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.
    Amar MJ, Sakurai T, Sakurai-Ikuta A, Sviridov D, Freeman L, Ahsan L, Remaley AT.
    J Pharmacol Exp Ther; 2015 Feb 29; 352(2):227-35. PubMed ID: 25395590
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.
    Sakurai T, Sakurai A, Vaisman BL, Amar MJ, Liu C, Gordon SM, Drake SK, Pryor M, Sampson ML, Yang L, Freeman LA, Remaley AT.
    J Pharmacol Exp Ther; 2016 Feb 29; 356(2):341-53. PubMed ID: 26574515
    [Abstract] [Full Text] [Related]

  • 12. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject.
    Huff MW, Evans AJ, Wolfe BM, Connelly PW, Maguire GF, Strong WL.
    J Lipid Res; 1990 Mar 29; 31(3):385-96. PubMed ID: 2341805
    [Abstract] [Full Text] [Related]

  • 13. Reduction of plasma triglycerides in apolipoprotein C-II transgenic mice overexpressing lipoprotein lipase in muscle.
    Pulawa LK, Jensen DR, Coates A, Eckel RH.
    J Lipid Res; 2007 Jan 29; 48(1):145-51. PubMed ID: 17018885
    [Abstract] [Full Text] [Related]

  • 14. [Primary hypertriglyceridemia].
    Kotake H, Oikawa S.
    Nihon Rinsho; 1999 Dec 29; 57(12):2782-8. PubMed ID: 10638213
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
    Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL.
    J Clin Invest; 1992 Nov 29; 90(5):1889-900. PubMed ID: 1430212
    [Abstract] [Full Text] [Related]

  • 16. Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation.
    Silbernagel G, Chen YQ, Rief M, Kleber ME, Hoffmann MM, Stojakovic T, Stang A, Sarzynski MA, Bouchard C, März W, Qian YW, Scharnagl H, Konrad RJ.
    Eur Heart J; 2023 Jul 01; 44(25):2335-2345. PubMed ID: 37155355
    [Abstract] [Full Text] [Related]

  • 17. ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency.
    Gerritsen G, van der Hoogt CC, Schaap FG, Voshol PJ, Kypreos KE, Maeda N, Groen AK, Havekes LM, Rensen PC, van Dijk KW.
    J Lipid Res; 2008 May 01; 49(5):1048-55. PubMed ID: 18263930
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.
    Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS.
    J Lipid Res; 2002 Dec 01; 43(12):2136-45. PubMed ID: 12454276
    [Abstract] [Full Text] [Related]

  • 19. Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach.
    Reimund M, Wolska A, Risti R, Wilson S, Sviridov D, Remaley AT, Lookene A.
    Biochem Biophys Res Commun; 2019 Oct 29; 519(1):67-72. PubMed ID: 31477272
    [Abstract] [Full Text] [Related]

  • 20. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
    Sun HY, Lin CC, Lee JC, Wang SW, Cheng PN, Wu IC, Chang TT, Lai MD, Shieh DB, Young KC.
    Gut; 2013 Aug 29; 62(8):1193-203. PubMed ID: 22689516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.